USFDA concludes inspection at Eugia Pharma with zero observations

The inspection closed with zero observations and a classification of No Action Indicated (NAI

120
USFDA Inspection
USFDA Inspection

Last Updated on November 11, 2024 by The Health Master

The United States Food and Drug Administration (USFDA) has approved a Formulation manufacturing facility of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of Aurobindo Pharma.

The USFDA inspected Unit I, a Formulation manufacturing facility of Eugia Pharma Specialities situated at Koltur Village, Shameerpet, Medchal District, Telangana, from July 17-26, 2023. 

“The inspection closed with zero observations and a classification of No Action Indicated (NAI),” Hyderabad-based Aurobindo said in a release.

Types of inspections done by USFDA: Read in detail

USFDA issues Form 483 to Pharma Companies: Let’s know all about it

USFDA Drug Approval Process: A Comprehensive Guide

10 Facts about USFDA Approval of Drug

Understanding GMP, cGMP, and WHO-GMP

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news